247 related articles for article (PubMed ID: 27079208)
1. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
Eur J Ophthalmol; 2016 Aug; 26(5):425-30. PubMed ID: 27079208
[TBL] [Abstract][Full Text] [Related]
2. Response to anti-VEGF-A treatment of endothelial cells in vitro.
Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
Exp Eye Res; 2016 May; 146():128-136. PubMed ID: 26771090
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
4. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
Chae JB; Rho CR; Shin JA; Lyu J; Kang S
Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
[TBL] [Abstract][Full Text] [Related]
5. Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia.
Bahrami B; Shen W; Zhu L; Zhang T; Chang A; Gillies MC
Clin Exp Ophthalmol; 2019 Nov; 47(8):1074-1081. PubMed ID: 31265210
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
[TBL] [Abstract][Full Text] [Related]
7. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
Dinç E; Ayaz L; Kurt AH
J Ocul Pharmacol Ther; 2018 May; 34(4):346-353. PubMed ID: 29389239
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
Sheu SJ; Chao YM; Liu NC; Chan JY
Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
[TBL] [Abstract][Full Text] [Related]
9. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
[TBL] [Abstract][Full Text] [Related]
10. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
Malik D; Tarek M; Caceres del Carpio J; Ramirez C; Boyer D; Kenney MC; Kuppermann BD
Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
[TBL] [Abstract][Full Text] [Related]
11. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.
Vo TA; Abedi S; Schneider K; Chwa M; Kenney MC
Exp Eye Res; 2018 Dec; 177():112-116. PubMed ID: 30071215
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
[TBL] [Abstract][Full Text] [Related]
13. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
Ranjbar M; Brinkmann MP; Zapf D; Miura Y; Rudolf M; Grisanti S
Cell Physiol Biochem; 2016; 38(2):737-47. PubMed ID: 26871551
[TBL] [Abstract][Full Text] [Related]
14. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
Klettner A; Recber M; Roider J
Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
[TBL] [Abstract][Full Text] [Related]
16. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
[TBL] [Abstract][Full Text] [Related]
17. Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.
De Cillà S; Farruggio S; Vujosevic S; Raina G; Filippini D; Gatti V; Clemente N; Mary D; Vezzola D; Casini G; Rossetti L; Grossini E
Cell Physiol Biochem; 2017; 42(5):1725-1738. PubMed ID: 28743128
[TBL] [Abstract][Full Text] [Related]
18. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept and Ranibizumab Modulate Retinal Pigment Epithelial Cells Function by Acting on Their Cross Talk with Vascular Endothelial Cells.
De Cillà S; Farruggio S; Cocomazzi G; Mary D; Alkabes M; Rossetti L; Vujosevic S; Grossini E
Cell Physiol Biochem; 2020 Feb; 54(2):161-179. PubMed ID: 32045141
[TBL] [Abstract][Full Text] [Related]
20. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
